The state of New Hampshire has announced that it will be joining a $60m vaginal mesh liability compensation settlement against medical device producer CR Bard.
Currently the attorneys general for 48 US states and the District of Columbia have been added to the class action that alleges CR Bard did not recognize the possible issues with their transvaginal surgical mesh devices. These devices are implemented in order to address urinary incontinence by reinforcing the vaginal floor which can be harmed due to eroded organs. This condition can result in major pain during during the act of sexual intercourse and or while voiding bowels, etc.
The expense of treating those who are suffering due to the mesh devices is taken on by each states as it funds Medicaid and state insurance health plans. CR Bard is a New Jersey-based firm that had $17.3bn in revenue last year. New Hampshire’s is due to be awarded $661,071 as its portion of the legal action settlement.
Along with this CR Bard will have to fight other claims, made by individual plaintiffs. This includes around 5,000 federal legal cases in the state of Ohio and 3,000 legal actions in Rhode Island.
CR Bard discontinued the vaginal mesh device production in 2012. This move came in the aftermath of a $3.6m compensation settlement action for one woman. The claim had been submitted in relation to suffering caused by a vaginal mesh device.
CJ Bard released a statement which said: “Bard and BD have denied any wrongdoing and all allegations included in the litigation and chose to settle the matter to avoid the time and expense of further litigation.”
These class action legal cases claim that Atrium’s C-QUR hernia mesh products, which are lined with a fish oil derivative as a possible solution to adverse reactions to the treatment, are actually inflicting additional complications.
A legal representative for Atrium said: “We think there is a similarity, because there is the same underlying material involved. We are hoping they take a closer look.”